257 results on '"Lacroix-Triki, M."'
Search Results
2. Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers
- Author
-
Alfaro, A., Catelain, C., El-Masri, H., Rameau, P., Lacroix-Triki, M., Scoazec, JY., Marty, V., Mosele, F., and Pistilli, B.
- Published
- 2024
- Full Text
- View/download PDF
3. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial
- Author
-
Penault-Llorca, F., Dalenc, F., Chabaud, S., Cottu, P., Allouache, D., Cameron, D., Grenier, J., Venat Bouvet, L., Jegannathen, A., Campone, M., Debled, M., Hardy-Bessard, A.-C., Giacchetti, S., Barthelemy, P., Kaluzinski, L., Mailliez, A., Mouret-Reynier, M.-A., Legouffe, E., Cayre, A., Martinez, M., Delbaldo, C., Mollon-Grange, D., Macaskill, E.J., Sephton, M., Stefani, L., Belgadi, B., Winter, M., Orfeuvre, H., Lacroix-Triki, M., Bonnefoi, H., Bliss, J., Canon, J.-L., Lemonnier, J., Andre, F., and Bachelot, T.
- Published
- 2024
- Full Text
- View/download PDF
4. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
- Author
-
Grinda, T., Antoine, A., Jacot, W., Blaye, C., Cottu, P.-H., Diéras, V., Dalenc, F., Gonçalves, A., Debled, M., Patsouris, A., Mouret-Reynier, M.-A., Mailliez, A., Clatot, F., Levy, C., Ferrero, J.-M., Desmoulins, I., Uwer, L., Petit, T., Jouannaud, C., Lacroix-Triki, M., Deluche, E., Robain, M., Courtinard, C., Bachelot, T., Brain, E., Pérol, D., and Delaloge, S.
- Published
- 2021
- Full Text
- View/download PDF
5. 189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)
- Author
-
Pistilli, B., primary, Ibrahimi, N., additional, Lacroix-Triki, M., additional, D'Hondt, V., additional, Vicier, C., additional, Frenel, J-S., additional, Dalenc, F., additional, Bachelot, T., additional, Benderra, M-A., additional, Loirat, D., additional, Ducoulombier, A., additional, Mayeur, D., additional, Nachabeh, G.B., additional, Serhal, K., additional, Corcos, N., additional, Sellami, D., additional, Michiels, S., additional, André, F., additional, Mosele, M.F., additional, and Montagnac, G., additional
- Published
- 2023
- Full Text
- View/download PDF
6. 121TiP LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- early breast cancer at very low risk of metastasis
- Author
-
Deluche, E., primary, Michiels, S., additional, Fric, D., additional, Perrin, C., additional, Bailleux, C., additional, Bachelot, T., additional, Kivok Yun, P. Ko, additional, De Rauglaudre, G., additional, Mouret Reynier, M.A., additional, Le Scodan, R., additional, Luis, I.V. Vaz, additional, Lacroix-Triki, M., additional, Guyonneau, C., additional, and André, F., additional
- Published
- 2023
- Full Text
- View/download PDF
7. Classification et signatures moléculaires des cancers du sein en 2017
- Author
-
Joyon, N., Penault-Llorca, F., and Lacroix-Triki, M.
- Published
- 2017
- Full Text
- View/download PDF
8. Deep Learning Allows Assessment of Risk of Metastatic Relapse from Invasive Breast Cancer Histological Slides
- Author
-
Garberis, I., primary, Gaury, V., additional, Saillard, C., additional, Drubay, D., additional, Elgui, K., additional, Schmauch, B., additional, Jaeger, A., additional, Herpin, L., additional, Linhart, J., additional, Sapateiro, M., additional, Bernigole, F., additional, Kamoun, A., additional, Bendjebbar, E., additional, de Lavergne, A., additional, Dubois, R., additional, Auffret, M., additional, Guillou, L., additional, Bousaid, I., additional, Azoulay, M., additional, Lemonnier, J., additional, Sefta, M., additional, Jacquet, A., additional, Sarrazin, A., additional, Reboud, J-F, additional, Brulport, F., additional, Dachary, J., additional, Pistilli, B., additional, Delaloge, S., additional, Courtiol, P., additional, André, F., additional, Aubert, V., additional, and Lacroix-Triki, M., additional
- Published
- 2022
- Full Text
- View/download PDF
9. Étude de performance de CLEO Mitose, un outil de détection automatique de mitose pour le cancer invasif du sein
- Author
-
Simmat, C., primary, Guichard, L., additional, Sockeel, S., additional, Pozin, N., additional, Lacroix-Triki, M., additional, Miquel, C., additional, Sockeel, M., additional, and Prevot, S., additional
- Published
- 2022
- Full Text
- View/download PDF
10. LBA72 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial
- Author
-
Mosele, M.F., primary, Lusque, A., additional, Dieras, V.C., additional, Deluche, E., additional, Ducoulombier, A., additional, Pistilli, B., additional, Bachelot, T., additional, Viret, F., additional, Levy, C., additional, Pradat, Y.C., additional, Tran, D.T.N., additional, Droin, N., additional, Kobayashi, M., additional, Kakewaga, T., additional, Deloger, M., additional, Job, B., additional, Jimenez, M., additional, Lacroix-Triki, M., additional, and André, F., additional
- Published
- 2022
- Full Text
- View/download PDF
11. 343MO Unraveling the mechanisms of action and resistance to trastuzumab deruxtecan (T-DXd): Supplementary biomarker analyses from DAISY trial
- Author
-
Mosele, M.F., Lusque, A., Dieras, V.C., Deluche, E., Ducoulombier, A., Pistilli, B., Bachelot, T., Viret, F., Levy, C., Pradat, Y.C., Signolle, N., Le Bescond, L., Tran, D., Droin, N., Kobayashi, M., Kakewaga, T., Deloger, M., Jimenez, M., Lacroix-Triki, M., and André, F.
- Published
- 2024
- Full Text
- View/download PDF
12. 340O Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC)
- Author
-
Pistilli, B., Pierotti, L., Lacroix-Triki, M., Vicier, C., Frenel, J-S., D'Hondt, V., Dalenc, F., Bachelot, T., Ducoulombier, A., Benderra, M-A., Loirat, D., Mayeur, D., Nachabeh, G.B., Sporchia, A., Suto, F., Michiels, S., Corcos, N., Mosele, M.F., André, F., and Montagnac, G.
- Published
- 2024
- Full Text
- View/download PDF
13. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer
- Author
-
Loi, S, Salgado, R, Adams, S, Pruneri, G, Francis, PA, Lacroix-Triki, M, Joensuu, H, Dieci, MV, Badve, S, Demaria, S, Gray, R, Munzone, E, Drubay, D, Lemonnier, J, Sotiriou, C, Kellokumpu-Lehtinen, PL, Vingiani, A, Gray, K, Andre, F, Denkert, C, Piccart, M, Roblin, E, Michiels, S, Loi, S, Salgado, R, Adams, S, Pruneri, G, Francis, PA, Lacroix-Triki, M, Joensuu, H, Dieci, MV, Badve, S, Demaria, S, Gray, R, Munzone, E, Drubay, D, Lemonnier, J, Sotiriou, C, Kellokumpu-Lehtinen, PL, Vingiani, A, Gray, K, Andre, F, Denkert, C, Piccart, M, Roblin, E, and Michiels, S
- Abstract
The importance of integrating biomarkers into the TNM staging has been emphasized in the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging system. In a pooled analysis of 2148 TNBC-patients in the adjuvant setting, TILs are found to strongly up and downstage traditional pathological-staging in the Pathological and Clinical Prognostic Stage Groups from the AJJC 8th edition Cancer Staging System. This suggest that clinical and research studies on TNBC should take TILs into account in addition to stage, as for example patients with stage II TNBC and high TILs have a better outcome than patients with stage I and low TILs.
- Published
- 2022
14. 18P Comparative genomic profiling of primary and locally recurrent luminal breast cancers (BC)
- Author
-
Rassy, E., primary, Garberis, I.J., additional, Tran Dien, A., additional, Scott, V., additional, Bouakka, I., additional, Bassil, J.J., additional, Lacroix-Triki, M., additional, Zanconati, F., additional, Giudici, F., additional, Generali, D., additional, Rouleau, E., additional, Lacroix, L., additional, André, F., additional, and Pistilli, B., additional
- Published
- 2022
- Full Text
- View/download PDF
15. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
- Author
-
El Bairi, K., Haynes, H. R., Blackley, E., Fineberg, S., Shear, J., Turner, S., de Freitas, J. R., Sur, D., Amendola, L. C., Gharib, M., Kallala, A., Arun, I., Azmoudeh-Ardalan, F., Fujimoto, L., Sua, L. F., Liu, S. -W., Lien, H. -C., Kirtani, P., Balancin, M., El Attar, H., Guleria, P., Yang, W., Shash, E., Chen, I. -C., Bautista, V., Do Prado Moura, J. F., Rapoport, B. L., Castaneda, C., Spengler, E., Acosta-Haab, G., Frahm, I., Sanchez, J., Castillo, M., Bouchmaa, N., Md Zin, R. R., Shui, R., Onyuma, T., Husain, Z., Willard-Gallo, K., Coosemans, A., Perez, E. A., Provenzano, E., Ericsson, P. G., Richardet, E., Mehrotra, R., Sarancone, S., Ehinger, A., Rimm, D. L., Bartlett, J. M. S., Viale, G., Denkert, C., Hida, A. I., Sotiriou, C., Loibl, S., Hewitt, S. M., Badve, S., Symmans, W. F., Kim, R. S., Pruneri, G., Goel, S., Francis, P. A., Inurrigarro, G., Yamaguchi, R., Garcia-Rivello, H., Horlings, H., Afqir, S., Salgado, R., Adams, S., Kok, M., Dieci, M. V., Michiels, S., Demaria, S., Loi, S., Schelfhout, V., Arbzadeh, E., Bondanar, A., Reyes, S. A. G., Ruz, J. R., Kang, J., Xiang, L., Zimovjanova, M., Togores, P., Ozturk, T., Patil, A., Corpa, M., Whitehouse, A., Tan, B., de Paula, A., Rossetti, C., Lang-Schwarz, C., Mahon, S., Giacometti, C., Linderholm, B., Deman, F., Montagna, G., Gong, G., Pavcovich, M., Chaer, Y., Cabrero, I. A., de Brito, M. L., Ilieva, N., Fulop, A., Souza, M., Bilancia, D., Idowu, M., Johri, R., Szpor, J., Bachani, L., Schmitt, F., Giannotti, M., Kurebayashi, Y., Ramirez, B. E. A., Salido, E., Bortesi, L., Bonetto, S., Elomina, K., Lopez, P., Sharma, V., Edirisinghe, A., Mathur, D., Sahay, A., Mouloud, M. A., Giang, C. H., Mukolwe, E., Kiruka, E., Samberg, N., Abe, N., Brown, M., Millar, E., X. B., Li, Yuan, Z., Pasupathy, A., Miele, R., Luff, R., e Porfirio, M. M. A., Ajemba, O., Soni, R., Orvieto, E., Dimaio, M., Thomas, J., Merard, R., Subramaniam, M. M., Apolinario, T., Preda, O., Preda, R., Makanga, A., Maior, M. S., Li, L., Saghatchian, M., Saurine, T., Janssen, E., Cochran, J., Vlada, N., Cappellesso, R., Elfer, K., Hollick, M., Desai, S., Oner, G., Schreurs, A., Liu, S., Perera, R., Mercurio, P., Garcia, F., Hosny, K., Matsumoto, H., van Deurzen, C., Bianchini, G., Coban, I., Jahangir, A., Rahman, A., Stover, D., Luz, P., Martel, A., Waumans, Y., Stenzinger, A., Cortes, J., Dimitrova, P., Nauwelaers, I., Velasco, M., Fan, F., Akturk, G., Firer, M., Roxanis, I., Schneck, M., Wen, H., Cockenpot, V., Konstantinov, A., Calatrava, A., Vidya, M. N., Choi, H. J., Jank, P., Ciinen, A. H., Sabanathan, D., Floris, G., Hoeflmayer, D., Hamada, T., Laudus, N., Grigoriadis, A., Porcellato, I., Acs, B., Miglietta, F., Parrodi, J., Clunie, D., Calhoun, B., F. -I., Lu, Lefevre, A., Tabbarah, S., Tran, W., Garcia-murillas, I., Jelinic, P., Boeckx, C., Souza, S., Cebollero, M. C., Felip, E., Rendon, J. L. S., El Gabry, E., Saltz, J., Bria, E., Garufi, G., Hartman, J., Sebastian, M., Olofsson, H., Kooreman, L., Cucherousset, J., Mathieu, M. -C., Ballesteros-Merino, C., Siziopikou, P., Fong, J., Klein, M., Qulis, I. R. I., Wesseling, J., Bellolio, E., Araya, J. C., Naber, S., Cheang, M., Castellano, I., Ales, A., Laenkholm, A. -V., Kulka, J., Quinn, C., Sapino, A., Amendoeira, I., Marchio, C., Braybrooke, J., Vincent-Salomon, A., Korski, K. P., Sofopoulos, M., Stovgaard, E. I. S., Bianchi, S., Bago-Horvath, Z., Yu, C., Regitnig, P., Hall, S., Kos, Z., Sant, S., Tille, J. -C., Gallas, B., Bethmann, D., Savas, P., Mendes, L., Soler, T., van Seijen, M., Gruosso, T., Quintana, A., Giltnane, J., Van den Eynden, G., Duregon, E., de Cabo, R., Recamo, P. C., Gaboury, L., Zimmerman, J., Pop, C. S., Wernicke, A., Williams, D., Gill, A., Solomon, B., Thapa, B., Farshid, G., Gilham, L., Christie, M., O'Toole, S., Hendry, S., Fox, S. B., Luen, S. J., Lakhani, S. R., Fuchs, T., John, T., Brcic, I., Hainfellner, J., Sigurd, L., Preusser, M., Poortmans, P., Decaluwe, A., Carey, C., Colpaert, C., Larsimont, D., Peeters, D., Broeckx, G., van de Vijver, K., Buisseret, L., Dirix, L., Hertoghs, M., Piccart, M., Ignatiadis, M., Van Bockstal, M., Sirtaine, N., Vermeulen, P., de Wind, R., Declercq, S., Gevaert, T., Haibe-Kans, B., Nelson, B. H., Watson, P. H., Leung, S., Nielsen, T., Shi, L., Balslev, E., Thagaard, J., Almangush, A., Makitie, A., Joensuu, H., Lundin, J., Drubay, D., Roblin, E., Andre, F., Penault-Llorca, F., Lemonnier, J., Adam, J., Lacroix-Triki, M., Ternes, N., Radosevic-Robin, N., Klaushen, F., Weber, K., Harbeck, N., Gluz, O., Wienert, S., Cserni, G., Vingiani, A., Criscitiello, C., Solinas, C., Curigliano, G., Konishi, E., Suzuki, E., Yoshikawa, K., Kawaguchi, K., Takada, M., Toi, M., Ishida, M., Shibata, N., Saji, S., Kogawa, T., Sakatani, T., Okamoto, T., Moriya, T., Kataoka, T., Shimoi, T., Sugie, T., Mukohara, T., Shu, Y., Kikawa, Y., Kozuka, Y., Sayed, S., Rahayu, R., Ramsaroop, R., Senkus-Konefka, E., Chmielik, E., Cardoso, F., Ribeiro, J., Chan, J., Dent, R., Martin, M., Hagen, C., Guerrero, A., Rojo, F., Comerma, L., Nuciforo, P., Serrano, V. V., Camaea, V. P., Steenbruggen, T., Ciompi, F., Nederlof, I., Jan, Hudecek, van der Laak, J., van den Berg, J., Voorwerk, L., van de Vijver, M., de Maaker, M., Linn, S., Mckenzie, H., Somaiah, N., Tutt, A., Swanton, C., Hiley, C., Moore, D. A., Hall, J. A., Le Quesne, J., Jabbar, K. A., al Bakir, M., Hills, R., Irshad, S., Yuan, Y., Li, Z., Liu, M., Klein, J., Fadare, O., Thompson, A., Lazar, A. J., Gown, A., Lo, A., Garrido Castro, A. C., Madabhushi, A., Moreira, A., Richardson, A., Beck, A. H., Bellizzi, A. M., Wolff, A., Harbhajanka, A., Sharma, A., Cimino-Mathews, A., Srinivasan, A., Singh, B., Chennubhotla, C. S., Chauhan, C., Dillon, D. A., Zardavas, D., Johnson, D. B., Thompson, A. E., Brogi, E., Reisenbichler, E., Huang, E., Hirsch, F. R., Mcarthur, H., Ziai, J., Brock, J., Kerner, J., Zha, J., Lennerz, J. K., Carter, J. M., Reis-Filho, J., Sparano, J., Balko, J. M., Pogue-Geile, K., Steele, K. E., Blenman, K. R. M., Allison, K. H., Pusztai, L., Cooper, L., Estrada, V. M., Flowers, M., Robson, M., Rebelatto, M. C., Hanna, M. G., Goetz, M. P., Khojasteh, M., Sanders, M. E., Regan, M. M., Misialek, M., Amgad, M., Tung, N., Singh, R., Huang, R., Pierce, R. H., Leon-Ferre, R., Swain, S., Ely, S., Kim, S. -R., Bedri, S., Paik, S., Schnitt, S., D'Alfons, T., Kurkure, U., Bossuyt, V., Tong, W., Wang, Y., Dos Anjos, C. H., Gaire, F., Van Diest, P. J., El Bairi, Khalid [0000-0002-8414-4145], de Freitas, Juliana Ribeiro [0000-0003-4978-7273], Sur, Daniel [0000-0002-0926-4614], Amendola, Luis Claudio [0000-0002-6404-450X], Azmoudeh-Ardalan, Farid [0000-0003-4701-0532], Kirtani, Pawan [0000-0002-2343-7016], Yang, Wenxian [0000-0002-5349-9680], Castillo, Miluska [0000-0002-0111-3176], Provenzano, Elena [0000-0003-3345-3965], Mehrotra, Ravi [0000-0001-9453-1408], Ehinger, Anna [0000-0001-9225-7396], Rimm, David L [0000-0001-5820-4397], Bartlett, John MS [0000-0002-0347-3888], Denkert, Carsten [0000-0002-2249-0982], Hida, Akira I [0000-0002-4486-8819], Sotiriou, Christos [0000-0002-5745-9977], Hewitt, Stephen M [0000-0001-8283-1788], Badve, Sunil [0000-0001-8861-9980], Symmans, William Fraser [0000-0002-1526-184X], Goel, Shom [0000-0001-8329-9084], Francis, Prudence A [0000-0002-7207-9286], Horlings, Hugo [0000-0003-4782-8828], Salgado, Roberto [0000-0002-1110-3801], Demaria, Sandra [0000-0003-4426-0499], Loi, Sherene [0000-0001-6137-9171], Apollo - University of Cambridge Repository, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'anatomie pathologique, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), and UNICANCER
- Subjects
Oncology ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,TRASTUZUMAB ,Improved survival ,MICROENVIRONMENT ,Review Article ,SUBTYPES ,NEOADJUVANT CHEMOTHERAPY ,0302 clinical medicine ,Breast cancer ,Ecology,Evolution & Ethology ,PROGNOSTIC-SIGNIFICANCE ,Medicine and Health Sciences ,Pharmacology (medical) ,TUMOR-INFILTRATING LYMPHOCYTES ,Stage (cooking) ,RC254-282 ,Chemical Biology & High Throughput ,0303 health sciences ,Human Biology & Physiology ,Genome Integrity & Repair ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,ASSOCIATION ,3. Good health ,030220 oncology & carcinogenesis ,Biomarker (medicine) ,Life Sciences & Biomedicine ,Genetics & Genomics ,medicine.medical_specialty ,chemical and pharmacologic phenomena ,International Immuno-Oncology Biomarker Working Group ,Predictive markers ,03 medical and health sciences ,Signalling & Oncogenes ,SDG 3 - Good Health and Well-being ,Internal medicine ,692/53/2423 ,medicine ,Radiology, Nuclear Medicine and imaging ,In patient ,030304 developmental biology ,Computational & Systems Biology ,Science & Technology ,IDENTIFICATION ,business.industry ,review-article ,Cancer ,03.01. Általános orvostudomány ,Immunotherapy ,Tumour Biology ,medicine.disease ,PREDICTIVE-VALUE ,692/4028/67/1347 ,Programmed death 1 ,business ,FREE SURVIVAL - Abstract
The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC. ispartof: NPJ BREAST CANCER vol:7 issue:1 ispartof: location:United States status: published
- Published
- 2021
16. Cancers du sein T1a,b N0 M0 (RPC 2013)
- Author
-
Cottu, P., Lacroix-Triki, M., Jacot, W., Belkacemi, Y., Dalenc, F., Cottu, P., Rodrigues, M., and Coeffic, D.
- Published
- 2013
- Full Text
- View/download PDF
17. 159P SiMosein, a real-life prospective evaluation of EndoPredict use in early ER-positive, HER2-negative breast cancers
- Author
-
Lehmann-Che, J., primary, Wong, J., additional, Lacroix, L., additional, Lacroix-Triki, M., additional, Arnould, L., additional, Lamy, P.J., additional, Quillien, V., additional, Godey, F., additional, Soubeyran, I., additional, MacGrogan, G., additional, Haudebourg, J., additional, Dupé, M., additional, Heymann, M-F., additional, Raoux, D., additional, Manz, S., additional, Tallet, A., additional, Padilla, N., additional, Dainese, L., additional, Karayan-Tapon, L., additional, and Penault-Llorca, F., additional
- Published
- 2021
- Full Text
- View/download PDF
18. 1124O Prediction of distant relapse in patients with invasive breast cancer from deep learning models applied to digital pathology slides
- Author
-
Garberis, I.J., primary, Saillard, C., additional, Drubay, D., additional, Schmauch, B., additional, Aubert, V., additional, Jaeger, A., additional, Sapateiro, M., additional, de Lavergne, A., additional, Kamoun, A., additional, Courtiol, P., additional, André, F., additional, and Lacroix-Triki, M., additional
- Published
- 2021
- Full Text
- View/download PDF
19. Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study
- Author
-
Bockstal, M.R. Van, François, A., Altinay, S., Arnould, L., Balkenhol, M.C., Broeckx, G., Burguès, O., Colpaert, C., Dedeurwaerdere, F., Dessauvagie, B., Duwel, V., Floris, G., Fox, S., Gerosa, C., Hastir, D., Jaffer, S., Kurpershoek, E., Lacroix-Triki, M., Laka, A., Lambein, K., MacGrogan, G.M., Marchiò, C., Martinez, M.D. Martin, Nofech-Mozes, S., Peeters, D., Ravarino, A., Reisenbichler, E., Resetkova, E., Sanati, S., Schelfhout, A.M., Schelfhout, V., Shaaban, A., Sinke, R., Stanciu-Pop, C.M., Deurzen, C.H. van, Vijver, K.K. van de, Rompuy, A.S. Van, Vincent-Salomon, A., Wen, H.Y., Wong, S., Bouzin, C., Galant, C., Bockstal, M.R. Van, François, A., Altinay, S., Arnould, L., Balkenhol, M.C., Broeckx, G., Burguès, O., Colpaert, C., Dedeurwaerdere, F., Dessauvagie, B., Duwel, V., Floris, G., Fox, S., Gerosa, C., Hastir, D., Jaffer, S., Kurpershoek, E., Lacroix-Triki, M., Laka, A., Lambein, K., MacGrogan, G.M., Marchiò, C., Martinez, M.D. Martin, Nofech-Mozes, S., Peeters, D., Ravarino, A., Reisenbichler, E., Resetkova, E., Sanati, S., Schelfhout, A.M., Schelfhout, V., Shaaban, A., Sinke, R., Stanciu-Pop, C.M., Deurzen, C.H. van, Vijver, K.K. van de, Rompuy, A.S. Van, Vincent-Salomon, A., Wen, H.Y., Wong, S., Bouzin, C., and Galant, C.
- Abstract
Item does not contain fulltext, High stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC) are associated with pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). Histopathological assessment of sTILs in TNBC biopsies is characterized by substantial interobserver variability, but it is unknown whether this affects its association with pCR. Here, we aimed to investigate the degree of interobserver variability in an international study, and its impact on the relationship between sTILs and pCR. Forty pathologists assessed sTILs as a percentage in digitalized biopsy slides, originating from 41 TNBC patients who were treated with NAC followed by surgery. Pathological response was quantified by the MD Anderson Residual Cancer Burden (RCB) score. Intraclass correlation coefficients (ICCs) were calculated per pathologist duo and Bland-Altman plots were constructed. The relation between sTILs and pCR or RCB class was investigated. The ICCs ranged from -0.376 to 0.947 (mean: 0.659), indicating substantial interobserver variability. Nevertheless, high sTILs scores were significantly associated with pCR for 36 participants (90%), and with RCB class for eight participants (20%). Post hoc sTILs cutoffs at 20% and 40% resulted in variable associations with pCR. The sTILs in TNBC with RCB-II and RCB-III were intermediate to those of RCB-0 and RCB-I, with lowest sTILs observed in RCB-I. However, the limited number of RCB-I cases precludes any definite conclusions due to lack of power, and this observation therefore requires further investigation. In conclusion, sTILs are a robust marker for pCR at the group level. However, if sTILs are to be used to guide the NAC scheme for individual patients, the observed interobserver variability might substantially affect the chance of obtaining a pCR. Future studies should determine the 'ideal' sTILs threshold, and attempt to fine-tune the patient selection for sTILs-based de-escalation of NAC regimens. At present, there
- Published
- 2021
20. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
- Author
-
Kos, Z., Roblin, E., Kim, R. S., Michiels, S., Gallas, B. D., Chen, W., van de Vijver, K. K., Goel, S., Adams, S., Demaria, S., Viale, G., Nielsen, T. O., Badve, S. S., Symmans, W. F., Sotiriou, C., Rimm, D. L., Hewitt, S., Denkert, C., Loibl, S., Luen, S. J., Bartlett, J. M. S., Savas, P., Pruneri, G., Dillon, D. A., Cheang, M. C. U., Tutt, A., Hall, J. A., Kok, M., Horlings, H. M., Madabhushi, A., van der Laak, J., Ciompi, F., Laenkholm, A. -V., Bellolio, E., Gruosso, T., Fox, S. B., Araya, J. C., Floris, G., Hudecek, J., Voorwerk, L., Beck, A. H., Kerner, J., Larsimont, D., Declercq, S., Van den Eynden, G., Pusztai, L., Ehinger, A., Yang, W., Abduljabbar, K., Yuan, Y., Singh, R., Hiley, C., Bakir, M., Lazar, A. J., Naber, S., Wienert, S., Castillo, M., Curigliano, G., Dieci, M. -V., Andre, F., Swanton, C., Reis-Filho, J., Sparano, J., Balslev, E., Chen, I. -C., Stovgaard, E. I. S., Pogue-Geile, K., Blenman, K. R. M., Penault-Llorca, F., Schnitt, S., Lakhani, S. R., Vincent-Salomon, A., Rojo, F., Braybrooke, J. P., Hanna, M. G., Soler-Monso, M. T., Bethmann, D., Castaneda, C. A., Willard-Gallo, K., Sharma, A., Lien, H. -C., Fineberg, S., Thagaard, J., Comerma, L., Gonzalez-Ericsson, P., Brogi, E., Loi, S., Saltz, J., Klaushen, F., Cooper, L., Amgad, M., Moore, D. A., Salgado, R., Hyytiainen, A., Hida, A. I., Thompson, A., Lefevre, A., Gown, A., Lo, A., Sapino, A., Moreira, A. M., Richardson, A., Vingiani, A., Bellizzi, A. M., Guerrero, A., Grigoriadis, A., Garrido-Castro, A. C., Cimino-Mathews, A., Srinivasan, A., Acs, B., Singh, B., Calhoun, B., Haibe-Kans, B., Solomon, B., Thapa, B., Nelson, B. H., Ballesteroes-Merino, C., Criscitiello, C., Boeckx, C., Colpaert, C., Quinn, C., Chennubhotla, C. S., Solinas, C., Drubay, D., Sabanathan, D., Peeters, D., Zardavas, D., Hoflmayer, D., Johnson, D. B., Thompson, E. A., Perez, E., Elgabry, E. A., Blackley, E. F., Reisenbichler, E., Chmielik, E., Gaire, F., F. -I., Lu, Azmoudeh-Ardalan, F., Peale, F., Hirsch, F. R., Acosta-Haab, G., Farshid, G., Broeckx, G., Koeppen, H., Haynes, H. R., Mcarthur, H., Joensuu, H., Olofsson, H., Cree, I., Nederlof, I., Frahm, I., Brcic, I., Chan, J., Ziai, J., Brock, J., Weseling, J., Giltnane, J., Lemonnier, J., Zha, J., Ribeiro, J., Lennerz, J. K., Carter, J. M., Hartman, J., Hainfellner, J., Le Quesne, J., Juco, J. W., van den Berg, J., Sanchez, J., Cucherousset, J., Adam, J., Balko, J. M., Saeger, K., Siziopikou, K., Sikorska, K., Weber, K., Steele, K. E., Emancipator, K., El Bairi, K., Allison, K. H., Korski, K., Buisseret, L., Shi, L., Kooreman, L. F. S., Molinero, L., Estrada, M. V., Van Seijen, M., Lacroix-Triki, M., Sebastian, M. M., Balancin, M. L., Mathieu, M. -C., van de Vijver, M., Rebelatto, M. C., Piccart, M., Goetz, M. P., Preusser, M., Khojasteh, M., Sanders, M. E., Regan, M. M., Barnes, M., Christie, M., Misialek, M., Ignatiadis, M., de Maaker, M., Van Bockstal, M., Harbeck, N., Tung, N., Laudus, N., Sirtaine, N., Burchardi, N., Ternes, N., Radosevic-Robin, N., Gluz, O., Grimm, O., Nuciforo, P., Jank, P., Kirtani, P., Watson, P. H., Jelinic, P., Francis, P. A., Russell, P. A., Pierce, R. H., Hills, R., Leon-Ferre, R., de Wind, R., Shui, R., Leung, S., Tabbarah, S., Souza, S. C., O'Toole, S., Swain, S., Dudgeon, S., Willis, S., Ely, S., Bedri, S., Irshad, S., Liu, S., Hendry, S., Bianchi, S., Braganca, S., Paik, S., Luz, S., Gevaert, T., D'Alfons, T., John, T., Sugie, T., Kurkure, U., Bossuyt, V., Manem, V., Camaea, V. P., Tong, W., Tran, W. T., Wang, Y., Allory, Y., Husain, Z., Bago-Horvath, Z., Service de biostatistique et d'épidémiologie (SBE), Direction de la recherche clinique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Institut Gustave Roussy (IGR), Division of Pathology and Laboratory Medicine, Università degli Studi di Milano [Milano] (UNIMI)-European Institute of Oncology [Milan] (ESMO), Institut Jules Bordet [Bruxelles], Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Charité, Institute of Pathology, Translational Tumorpathology Unit, German Breast Group, University of the Sunshine Coast (USC), European Institute of Oncology [Milan] (ESMO), Breakthrough Breast Cancer Centre, London Institute of Cancer, Department of Pathology, The Netherlands Cancer Institute, Division of Experimental Therapy, The Netherlands Cancer Institute NKI/AvL, Odense University Hospital, Unité de génétique et biologie des cancers (U830), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Breast Medical Oncology [Houston], The University of Texas M.D. Anderson Cancer Center [Houston], Helsingborg Hospital, Division of Experimental Therapeutics [Milan, Italy], Département de médecine oncologique [Gustave Roussy], Cancer Research UK Lung Cancer Centre of Excellence [Londres, Royaume-Uni], University College of London [London] (UCL), Memorial Sloane Kettering Cancer Center [New York], Herlev and Gentofte Hospital, Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Southern Queensland (USQ), Pharmacogenomics Unit [Paris], Department of Genetics [Paris], Institut Curie [Paris]-Institut Curie [Paris], Instituto de Física Teórica UAM/CSIC (IFT), Universidad Autonoma de Madrid (UAM)-Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Ctr Biomol Struct & Org, University of Maryland [College Park], University of Maryland System-University of Maryland System, The University of Sydney, Breast Cancer Translational Research Laboratory, Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB)-Faculté de Médecine [Bruxelles] (ULB), Innovation North - Faculty of Information and Technology, Leeds Metropolitan University, Int Immuno-Oncology Biomarker, Graduate School, CCA - Cancer biology and immunology, Pathology, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Oncostat (U1018 (Équipe 2)), Institut Gustave Roussy (IGR)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Università degli Studi di Milano = University of Milan (UNIMI)-European Institute of Oncology [Milan] (ESMO), German Breast Group (GBG), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Universidad Autónoma de Madrid (UAM)-Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Gallas, Brandon D [0000-0001-7332-1620], van de Vijver, Koen K [0000-0002-2026-9790], Demaria, Sandra [0000-0003-4426-0499], Badve, Sunil S [0000-0001-8861-9980], Symmans, W Fraser [0000-0002-1526-184X], Rimm, David L [0000-0001-5820-4397], Savas, Peter [0000-0001-5999-428X], Hall, Jacqueline A [0000-0003-0708-1360], Horlings, Hugo M [0000-0003-4782-8828], van der Laak, Jeroen [0000-0001-7982-0754], Bellolio, Enrique [0000-0003-0079-5264], Araya, Juan Carlos [0000-0003-3501-8203], Floris, Giuseppe [0000-0003-2391-5425], Hudeček, Jan [0000-0003-1071-5686], Ehinger, Anna [0000-0001-9225-7396], Lazar, Alexander J [0000-0002-6395-4499], Castillo, Miluska [0000-0002-0111-3176], Curigliano, Giuseppe [0000-0003-1781-2518], Sparano, Joseph [0000-0002-9031-2010], Braybrooke, Jeremy P [0000-0003-1943-7360], Hanna, Matthew G [0000-0002-7536-1746], Willard-Gallo, Karen [0000-0002-1150-1295], Sharma, Ashish [0000-0002-1011-6504], Comerma, Laura [0000-0002-0249-4636], Gonzalez-Ericsson, Paula [0000-0002-6292-6963], Loi, Sherene [0000-0001-6137-9171], Cooper, Lee [0000-0002-3504-4965], Apollo - University of Cambridge Repository, Research Programs Unit, Heikki Joensuu / Principal Investigator, HUS Comprehensive Cancer Center, Department of Oncology, Medicum, Gallas, Brandon D. [0000-0001-7332-1620], van de Vijver, Koen K. [0000-0002-2026-9790], Badve, Sunil S. [0000-0001-8861-9980], Symmans, W. Fraser [0000-0002-1526-184X], Rimm, David L. [0000-0001-5820-4397], Hall, Jacqueline A. [0000-0003-0708-1360], Horlings, Hugo M. [0000-0003-4782-8828], Lazar, Alexander J. [0000-0002-6395-4499], Braybrooke, Jeremy P. [0000-0003-1943-7360], and Hanna, Matthew G. [0000-0002-7536-1746]
- Subjects
Oncology ,[SDV]Life Sciences [q-bio] ,THERAPY ,Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14] ,Prognostic markers ,0302 clinical medicine ,Breast cancer ,Medicine and Health Sciences ,Pharmacology (medical) ,Lymphocytes ,Stromal tumor ,health care economics and organizations ,0303 health sciences ,CHEMOTHERAPY ,Sciences bio-médicales et agricoles ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,3. Good health ,Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] ,PROGNOSTIC VALUE ,Clinical Practice ,030220 oncology & carcinogenesis ,Educational resources ,Immunosurveillance ,medicine.medical_specialty ,3122 Cancers ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,IMMUNITY ,lcsh:RC254-282 ,Article ,Limfòcits ,Càncer de mama ,03 medical and health sciences ,Gastrointestinal cancer ,SDG 3 - Good Health and Well-being ,Internal medicine ,692/53/2422 ,medicine ,Radiology, Nuclear Medicine and imaging ,Càncer gastrointestinal ,030304 developmental biology ,Predictive biomarker ,Tumor-infiltrating lymphocytes ,business.industry ,Médecine pathologie humaine ,medicine.disease ,Cancérologie ,Human medicine ,business ,SYSTEM ,631/67/580/1884 - Abstract
Stromal tumor-infiltrating lymphocytes (sTILs) are important prognostic and predictive biomarkers in triple-negative (TNBC) and HER2-positive breast cancer. Incorporating sTILs into clinical practice necessitates reproducible assessment. Previously developed standardized scoring guidelines have been widely embraced by the clinical and research communities. We evaluated sources of variability in sTIL assessment by pathologists in three previous sTIL ring studies. We identify common challenges and evaluate impact of discrepancies on outcome estimates in early TNBC using a newly-developed prognostic tool. Discordant sTIL assessment is driven by heterogeneity in lymphocyte distribution. Additional factors include: technical slide-related issues; scoring outside the tumor boundary; tumors with minimal assessable stroma; including lymphocytes associated with other structures; and including other inflammatory cells. Small variations in sTIL assessment modestly alter risk estimation in early TNBC but have the potential to affect treatment selection if cutpoints are employed. Scoring and averaging multiple areas, as well as use of reference images, improve consistency of sTIL evaluation. Moreover, to assist in avoiding the pitfalls identified in this analysis, we developed an educational resource available at www.tilsinbreastcancer.org/pitfalls., info:eu-repo/semantics/published
- Published
- 2020
21. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
- Author
-
Hudecek, J., Voorwerk, L., van Seijen, M., Nederlof, I., de Maaker, M., van den Berg, J., van de Vijver, K. K., Sikorska, K., Adams, S., Demaria, S., Viale, G., Nielsen, T. O., Badve, S. S., Michiels, S., Symmans, W. F., Sotiriou, C., Rimm, D. L., Hewitt, S. M., Denkert, C., Loibl, S., Loi, S., Bartlett, J. M. S., Pruneri, G., Dillon, D. A., Cheang, M. C. U., Tutt, A., Hall, J. A., Kos, Z., Salgado, R., Kok, M., Horlings, H. M., Hyytiainen, A., Hida, A. I., Thompson, A., Lefevre, A., Lazar, A. J., Gown, A., Lo, A., Sapino, A., Madabhushi, A., Moreira, A., Richardson, A., Vingiani, A., Beck, A. H., Bellizzi, A. M., Guerrero, A., Grigoriadis, A., Ehinger, A., Garrido-Castro, A., Vincent-Salomon, A., Laenkholm, A. -V., Sharma, A., Cimino-Mathews, A., Srinivasan, A., Acs, B., Singh, B., Calhoun, B., Haibe-Kans, B., Solomon, B., Thapa, B., Nelson, B. H., Gallas, B. D., Castaneda, C., Ballesteros-Merino, C., Criscitiello, C., Boeckx, C., Colpaert, C., Quinn, C., Chennubhotla, C. S., Swanton, C., Solinas, C., Hiley, C., Drubay, D., Bethmann, D., Moore, D. A., Larsimont, D., Sabanathan, D., Peeters, D., Zardavas, D., Hoflmayer, D., Johnson, D. B., Thompson, E. A., Brogi, E., Perez, E., Elgabry, E. A., Stovgaard, E. S., Blackley, E. F., Roblin, E., Reisenbichler, E., Bellolio, E., Balslev, E., Chmielik, E., Gaire, F., Andre, F., F. -I., Lu, Azmoudeh-Ardalan, F., Rojo, F., Gruosso, T., Ciompi, F., Peale, F., Hirsch, F. R., Klauschen, F., Penault-Llorca, F., Acosta Haab, G., Farshid, G., van den Eynden, G., Curigliano, G., Floris, G., Broeckx, G., Gonzalez-Ericsson, Koeppen, H., Haynes, H. R., Mcarthur, H., Joensuu, H., Olofsson, H., Lien, H. -C., Chen, I. -C., Cree, I., Frahm, I., Brcic, I., Chan, J., Ziai, J., Brock, J., Wesseling, J., Giltnane, J., Kerner, J. K., Thagaard, J., Braybrooke, J. P., van der Laak, J. A. W. M., Lemonnier, J., Zha, J., Ribeiro, J., Lennerz, J. K., Carter, J. M., Saltz, J., Hartman, J., Hainfellner, J., Quesne, J. L., Juco, J. W., Reis-Filho, J., Sanchez, J., Sparano, J., Cucherousset, J., Araya, J. C., Adam, J., Balko, J. M., Saeger, K., Siziopikou, K., Willard-Gallo, K., Weber, K., Pogue-Geile, K. L., Steele, K. E., Emancipator, K., Abduljabbar, K., El Bairi, K., Blenman, K. R. M., Allison, K. H., Korski, K., Pusztai, L., Comerma, L., Buisseret, L., Cooper, L. A. D., Shi, L., Kooreman, L. F. S., Molinero, L., Estrada, M. V., Lacroix-Triki, M., Al Bakir, M., Sebastian, M. M., van de Vijver, M., Balancin, M. L., Dieci, M. V., Mathieu, M. -C., Rebelatto, M. C., Piccart, M., Hanna, M. G., Goetz, M. P., Preusser, M., Khojasteh, M., Sanders, M. E., Regan, M. M., Barnes, M., Christie, M., Misialek, M., Ignatiadis, M., van Bockstal, M., Castillo, M., Amgad, M., Harbeck, N., Tung, N., Laudus, N., Sirtaine, N., Burchardi, N., Ternes, N., Radosevic-Robin, N., Gluz, O., Grimm, O., Nuciforo, P., Jank, P., Gonzalez-Ericsson, P., Kirtani, P., Jelinic, P., Watson, P. H., Savas, P., Francis, P. A., Russell, P. A., Singh, R., Kim, R. S., Pierce, R. H., Hills, R., Leon-Ferre, R., de Wind, R., Shui, R., De Clercq, S., Leung, S., Tabbarah, S., Souza, S. C., O'Toole, S., Swain, S., Dudgeon, S., Willis, S., Ely, S., Kim, S. -R., Bedri, S., Irshad, S., Liu, S. -W., Goel, S., Hendry, S., Bianchi, S., Braganca, S., Paik, S., Wienert, S., Fox, S. B., Luen, S. J., Naber, S., Schnitt, S. J., Sua, L. F., Lakhani, S. R., Fineberg, S., Soler, T., Gevaert, T., D'Alfonso, T., John, T., Sugie, T., Kurkure, U., Bossuyt, V., Manem, V., Camara, V. P., Tong, W., Chen, W., Yang, W., Tran, W. T., Wang, Y., Yuan, Y., Allory, Y., Husain, Z., Bago-Horvath, Z., Division of Pathology and Laboratory Medicine, Università degli Studi di Milano [Milano] (UNIMI)-European Institute of Oncology [Milan] (ESMO), Service de biostatistique et d'épidémiologie (SBE), Direction de la recherche clinique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Institut Gustave Roussy (IGR), Institut Jules Bordet [Bruxelles], Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Charité, Institute of Pathology, Translational Tumorpathology Unit, German Breast Group, Breast Cancer Translational Research Laboratory, Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB)-Faculté de Médecine [Bruxelles] (ULB), University of the Sunshine Coast (USC), European Institute of Oncology [Milan] (ESMO), Breakthrough Breast Cancer Centre, London Institute of Cancer, Department of Pathology, The Netherlands Cancer Institute, Division of Experimental Therapy, The Netherlands Cancer Institute NKI/AvL, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Hudeček, Jan [0000-0003-1071-5686], van de Vijver, Koen K [0000-0002-2026-9790], Demaria, Sandra [0000-0003-4426-0499], Badve, Sunil S [0000-0001-8861-9980], Symmans, William Fraser [0000-0002-1526-184X], Rimm, David L [0000-0001-5820-4397], Loi, Sherene [0000-0001-6137-9171], Hall, Jacqueline A [0000-0003-0708-1360], Horlings, Hugo M [0000-0003-4782-8828], Apollo - University of Cambridge Repository, van de Vijver, Koen K. [0000-0002-2026-9790], Badve, Sunil S. [0000-0001-8861-9980], Rimm, David L. [0000-0001-5820-4397], Hall, Jacqueline A. [0000-0003-0708-1360], Horlings, Hugo M. [0000-0003-4782-8828], Università degli Studi di Milano = University of Milan (UNIMI)-European Institute of Oncology [Milan] (ESMO), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Oncostat (U1018 (Équipe 2)), Institut Gustave Roussy (IGR)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, German Breast Group (GBG), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,medicine.medical_treatment ,MEDLINE ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Review Article ,lcsh:RC254-282 ,631/67/1857 ,Tumour biomarkers ,Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14] ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,692/53 ,Internal medicine ,Medicine and Health Sciences ,medicine ,Pharmacology (medical) ,Radiology, Nuclear Medicine and imaging ,692/4028/67/580 ,Stromal tumor ,Biomarkers ,Tumour immunology ,business.industry ,Risk management framework ,review-article ,Médecine pathologie humaine ,631/67/1347 ,Immunotherapy ,Sciences bio-médicales et agricoles ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] ,3. Good health ,Review article ,Clinical trial ,Cancérologie ,030104 developmental biology ,030220 oncology & carcinogenesis ,Biomarker (medicine) ,business - Abstract
Stromal tumor-infiltrating lymphocytes (sTILs) are a potential predictive biomarker for immunotherapy response in metastatic triple-negative breast cancer (TNBC). To incorporate sTILs into clinical trials and diagnostics, reliable assessment is essential. In this review, we propose a new concept, namely the implementation of a risk-management framework that enables the use of sTILs as a stratification factor in clinical trials. We present the design of a biomarker risk-mitigation workflow that can be applied to any biomarker incorporation in clinical trials. We demonstrate the implementation of this concept using sTILs as an integral biomarker in a single-center phase II immunotherapy trial for metastatic TNBC (TONIC trial, NCT02499367), using this workflow to mitigate risks of suboptimal inclusion of sTILs in this specific trial. In this review, we demonstrate that a web-based scoring platform can mitigate potential risk factors when including sTILs in clinical trials, and we argue that this framework can be applied for any future biomarker-driven clinical trial setting., info:eu-repo/semantics/published
- Published
- 2020
22. Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study
- Author
-
Dano, H, Altinay, S, Arnould, L, Bletard, N, Colpaert, C, Dedeurwaerdere, F, Dessauvagie, B, Duwel, V, Floris, G, Fox, S, Gerosa, C, Jaffer, S, Kurpershoek, E, Lacroix-Triki, M, Laka, A, Lambein, K, MacGrogan, GM, Marchio, C, Martinez, DM, Nofech-Mozes, S, Peeters, D, Ravarino, A, Reisenbichler, E, Resetkova, E, Sanati, S, Schelfhout, A-M, Schelfhout, V, Shaaban, AM, Sinke, R, Stanciu-Pop, CM, Stobbe, C, van Deurzen, CHM, Van de Vijver, K, Van Rompuy, A-S, Verschuere, S, Vincent-Salomon, A, Wen, H, Bouzin, C, Galant, C, Van Bockstal, MR, Dano, H, Altinay, S, Arnould, L, Bletard, N, Colpaert, C, Dedeurwaerdere, F, Dessauvagie, B, Duwel, V, Floris, G, Fox, S, Gerosa, C, Jaffer, S, Kurpershoek, E, Lacroix-Triki, M, Laka, A, Lambein, K, MacGrogan, GM, Marchio, C, Martinez, DM, Nofech-Mozes, S, Peeters, D, Ravarino, A, Reisenbichler, E, Resetkova, E, Sanati, S, Schelfhout, A-M, Schelfhout, V, Shaaban, AM, Sinke, R, Stanciu-Pop, CM, Stobbe, C, van Deurzen, CHM, Van de Vijver, K, Van Rompuy, A-S, Verschuere, S, Vincent-Salomon, A, Wen, H, Bouzin, C, Galant, C, and Van Bockstal, MR
- Abstract
Histopathological assessment of ductal carcinoma in situ, a nonobligate precursor of invasive breast cancer, is characterized by considerable interobserver variability. Previously, post hoc dichotomization of multicategorical variables was used to determine the "ideal" cutoffs for dichotomous assessment. The present international multicenter study evaluated interobserver variability among 39 pathologists who performed upfront dichotomous evaluation of 149 consecutive ductal carcinomas in situ. All pathologists independently assessed nuclear atypia, necrosis, solid ductal carcinoma in situ architecture, calcifications, stromal architecture, and lobular cancerization in one digital slide per lesion. Stromal inflammation was assessed semiquantitatively. Tumor-infiltrating lymphocytes were quantified as percentages and dichotomously assessed with a cutoff at 50%. Krippendorff's alpha (KA), Cohen's kappa and intraclass correlation coefficient were calculated for the appropriate variables. Lobular cancerization (KA = 0.396), nuclear atypia (KA = 0.422), and stromal architecture (KA = 0.450) showed the highest interobserver variability. Stromal inflammation (KA = 0.564), dichotomously assessed tumor-infiltrating lymphocytes (KA = 0.520), and comedonecrosis (KA = 0.539) showed slightly lower interobserver disagreement. Solid ductal carcinoma in situ architecture (KA = 0.602) and calcifications (KA = 0.676) presented with the lowest interobserver variability. Semiquantitative assessment of stromal inflammation resulted in a slightly higher interobserver concordance than upfront dichotomous tumor-infiltrating lymphocytes assessment (KA = 0.564 versus KA = 0.520). High stromal inflammation corresponded best with dichotomously assessed tumor-infiltrating lymphocytes when the cutoff was set at 10% (kappa = 0.881). Nevertheless, a post hoc tumor-infiltrating lymphocytes cutoff set at 20% resulted in the highest interobserver agreement (KA = 0.669). Despite upfront dichotomous eva
- Published
- 2020
23. Amélioration des pratiques en pathologie mammaire : organisation régionale de relecture par télépathologie dans le cadre du groupe SENOPATH
- Author
-
Caverivière, P., primary, Gordien, K., additional, Quintyn-Ranty, M.-L., additional, Mery, E., additional, Jamme-Lallemand, M., additional, Wuithier, P., additional, Palasse, J., additional, Reyre, J., additional, Laborie, V., additional, Maisongrosse, V., additional, Despax, B., additional, Rolland, V., additional, Jacob, M., additional, Bosc, R., additional, Escourrou, G., additional, Bauvin, E., additional, Manenc, J.-L., additional, Roché, H., additional, and Lacroix-Triki, M., additional
- Published
- 2013
- Full Text
- View/download PDF
24. Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients
- Author
-
Bertucci, F., Finetti, P., Roche, H., Le Doussal, J. M., Marisa, L., Martin, A. L., Lacroix-Triki, M., Blanc-Fournier, C., Jacquemier, J., Peyro-Saint-Paul, H., Viens, P., Sotiriou, C., Birnbaum, D., and Penault-Llorca, F.
- Published
- 2013
- Full Text
- View/download PDF
25. 161O Randomized preoperative window of opportunity (WOO) study with the CDK4/6 inhibitor abemaciclib in early breast cancer (EBC) patients and differential gene expression pathway analyses with palbociclib
- Author
-
Arnedos, M., primary, Chaltiel, D., additional, Cheaib, B., additional, Drubay, D., additional, Gentien, D., additional, Vieillefon, A., additional, Scott, V., additional, Bouakka, I., additional, Adam, J., additional, Garberis, I.J., additional, Rimareix, F., additional, Leymarie, N., additional, Viansone, A.A., additional, Lacroix-Triki, M., additional, Michiels, S., additional, and André, F., additional
- Published
- 2020
- Full Text
- View/download PDF
26. Altérations de l’expression, et implications pronostique et thérapeutique, des protéines régulatrices de l’épissage des ARNm dans les cancers du sein
- Author
-
Lacroix-Triki, M., primary, Dupuy, J. F., additional, Dalenc, F., additional, Dejean, S., additional, Besse, P., additional, Roché, H., additional, and Vagner, S., additional
- Published
- 2007
- Full Text
- View/download PDF
27. Comment prouver l’origine mammaire d’une métastase prévalente ? Y aurait-il un intérêt à biopsier les métastases d’un cancer du sein connu ?
- Author
-
Dalenc, F., primary and Lacroix-Triki, M., additional
- Published
- 2007
- Full Text
- View/download PDF
28. Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions
- Author
-
MacGrogan, G, Arnould, L, de Mascarel, I, Vincent-Salomon, A, Penault-Llorca, F, Lacroix-Triki, M, Bibeau, F, Baranzelli, M C, Fridman, V, Antoine, M, Bécette, V, Brouste, V, Jacquemier, J, and Mathoulin-Pélissier, S
- Published
- 2008
29. 147P Blind validation of an AI-based tool for predicting distant relapse from breast cancer HES stained slides
- Author
-
Garberis, I.J., Gaury, V., Aubert, V., Drubay, D., Saillard, C., Elgui, K., F. Bernigole, Jacquet, A., André, F., and Lacroix-Triki, M.
- Published
- 2022
- Full Text
- View/download PDF
30. OC-0153 Immune infiltrate modulation induced by preoperative radiotherapy in breast cancer patients
- Author
-
Perez, A. Matias, primary, Bardet, A., additional, Lacroix-Triki, M., additional, Riet, F., additional, Mathieu, M.C., additional, Deutsch, E., additional, Michiels, S., additional, and Rivera, S., additional
- Published
- 2019
- Full Text
- View/download PDF
31. Abstract P4-08-23: EndoPredict prognostic signature in pN1mi, estrogen receptor-positive breast cancer: analysis of the French national registry for molecular signatures
- Author
-
LaCroix-Triki, M, primary, Arnould, L, additional, MacGrogan, G, additional, Penault-Llorca, F, additional, Haudebourg, J, additional, Tas, P, additional, Garnier, A, additional, Vincent-Salomon, A, additional, Miquel, C, additional, Lehmann-Che, J, additional, Callens, C, additional, Quillien, V, additional, Cayre, A, additional, Lamy, P-J, additional, Rouleau, E, additional, and De Cremoux, P, additional
- Published
- 2019
- Full Text
- View/download PDF
32. Abstract P5-12-05: Phenotypic discordance between primary and metastatic breast cancer (MBC) in a large scale real-life multicentre French cohort
- Author
-
Lefevre, S, primary, Lusque, A, additional, Joyon, N, additional, Arnould, L, additional, Penault-Llorca, F, additional, MacGrogan, G, additional, Treilleux, I, additional, Vincent-Salomon, A, additional, Haudebourg, J, additional, Maran-Gonzalez, A, additional, Charafe-Jauffret, E, additional, Courtinard, C, additional, Franchet, C, additional, Verriele, V, additional, Brain, E, additional, Tas, P, additional, Delaloge, S, additional, Filleron, T, additional, and LaCroix-Triki, M, additional
- Published
- 2019
- Full Text
- View/download PDF
33. Abstract P3-11-10: Prosigna prognostic signature in pN1mi, estrogen receptor-positive breast cancer:the pN categorization impacts the BC risk stratification
- Author
-
Charafe-Jauffret, E, primary, Duprez-Paumier, R, additional, Berghian, A, additional, Penault-Llorca, F, additional, Dauplat, MM, additional, Boucraut, A, additional, Cohen, M, additional, Houvenaeghel, G, additional, Maroc, C, additional, Pradines, A, additional, Cayre, A, additional, Etancelin, P, additional, and Lacroix-triki, M, additional
- Published
- 2019
- Full Text
- View/download PDF
34. First-in-human trial design for W0101: A first-in-class antibody-drug conjugate targeting IGF-1R and identification of the target patient population
- Author
-
Gomez-Roca, C.A., primary, Garralda-Cabanas, E., additional, Cruzalegui, F., additional, Ausseil, F., additional, Zorza, G., additional, Delfour, O., additional, Besse, J., additional, Akla, B., additional, Gautier, S., additional, Adam, J., additional, Lacroix-Triki, M., additional, Passioukov, A., additional, Roche, R., additional, Pavlyuk, M., additional, and Massard, C., additional
- Published
- 2018
- Full Text
- View/download PDF
35. Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial
- Author
-
Arnedos, M., primary, Bayar, M.A., additional, Cheaib, B., additional, Scott, V., additional, Bouakka, I., additional, Valent, A., additional, Adam, J., additional, Leroux-Kozal, V., additional, Marty, V., additional, Rapinat, A., additional, Mazouni, C., additional, Sarfati, B., additional, Bieche, I., additional, Balleyguier, C., additional, Gentien, D., additional, Delaloge, S., additional, Lacroix-Triki, M., additional, Michiels, S., additional, and Andre, F., additional
- Published
- 2018
- Full Text
- View/download PDF
36. Abstract P1-07-07: Overtime distribution and predictors of local recurrences (LRs) in patients with hormone receptor positive (HR+) and node positive (N+) breast cancers (BCs): 10 -year follow-up analysis of UNICANCER-PACS 01 and PACS04 trials
- Author
-
Pistilli, B, primary, Filleron, T, additional, Mazouni, C, additional, Zingarello, A, additional, Lacroix-Triki, M, additional, Rivera, S, additional, Coudert, B, additional, Serin, D, additional, Canon, J-L, additional, Campone, M, additional, Bachelot, T, additional, Goncalves, A, additional, Levy, C, additional, Cottu, P, additional, Petit, T, additional, Eymard, J-C, additional, Tunon De Lara, C, additional, Roché, H, additional, Roca, L, additional, Lemonnier, J, additional, and Delaloge, S, additional
- Published
- 2018
- Full Text
- View/download PDF
37. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.
- Author
-
Hendry, Shona, Salgado, Roberto, Gevaert, Thomas, Russell, PA, John, T, Thapa, B, Christie, M, Van De Vijver, Kristin Inneke, Estrada, Mónica Valeria, Gonzales-Ericsson, PI, Sanders, Melinda M.E., Solomon, B, Solinas, Cinzia, Van den Eynden, Gert, Allory, Y, Preusser, Matthias, Hainfellner, J, Pruneri, Giancarlo, Vingiani, Andrea, Demaria, S, Symmans, Fraser, Nuciforo, Paolo, Comerma, L, Thompson, E A, Lakhani, Sunil S.R., Kim, Su Ryang, Schnitt, S, Colpaert, S, Sotiriou, Christos, Ignatiadis, Michail, Badve, S, Pierce, RH, Viale, G, Sirtaine, N., Pénault-Llorca, Frederique, Sugie, T, Fineberg, Daniel, Paik, Soon, Srinivasa, A, Richardson, A L, Wang, Y, Chmielik, E, Johnson, Douglas D.B., Balko, Justin J.M., Wienert, S, Bossuyt, V, Michiels, S, Ternest, N, Burchardi, N, Luen, SJ, Savas, P, Klauschen, F, Watson, PH, Nelson, BH, Criscitiello, Carmen, O'Toole, S, Larsimont, Denis, De Wind, Roland, Curigliano, G, André, F, Lacroix-Triki, M, Van de Vijver, Marc J, Rojo Fernandez, José Manuel, Floris, Giuseppe, Svatos, Bedrich, Sparano, Joseph, Rimm, David D.L., Nielsen, T, Kos, Z, Hewitt, Stephen M, Singh, Bal Ram, Farshid, G, Loibl, Sibylle, Allison, K H, Tung Ngu, Chan, Adams, S., Willard-Gallo, Karen, Horlings, HM, Gandhi, L, Moreira, A., Hirsch, F, Dieci, Maria V, Urbanowicz, M, Brcic, I, Korski, K, Gaire, F, Koeppen, A.H., Lo, A., Giltnane, Jennifer J.M., Rebelatto, MC, Steele, KE, Zha, J, Emancipator, K, Juco, JW, Denkert, Carsten, Reis-Filho, Jorge Sergio, Loi, Sherene, Fox, Stephen B, Hendry, Shona, Salgado, Roberto, Gevaert, Thomas, Russell, PA, John, T, Thapa, B, Christie, M, Van De Vijver, Kristin Inneke, Estrada, Mónica Valeria, Gonzales-Ericsson, PI, Sanders, Melinda M.E., Solomon, B, Solinas, Cinzia, Van den Eynden, Gert, Allory, Y, Preusser, Matthias, Hainfellner, J, Pruneri, Giancarlo, Vingiani, Andrea, Demaria, S, Symmans, Fraser, Nuciforo, Paolo, Comerma, L, Thompson, E A, Lakhani, Sunil S.R., Kim, Su Ryang, Schnitt, S, Colpaert, S, Sotiriou, Christos, Ignatiadis, Michail, Badve, S, Pierce, RH, Viale, G, Sirtaine, N., Pénault-Llorca, Frederique, Sugie, T, Fineberg, Daniel, Paik, Soon, Srinivasa, A, Richardson, A L, Wang, Y, Chmielik, E, Johnson, Douglas D.B., Balko, Justin J.M., Wienert, S, Bossuyt, V, Michiels, S, Ternest, N, Burchardi, N, Luen, SJ, Savas, P, Klauschen, F, Watson, PH, Nelson, BH, Criscitiello, Carmen, O'Toole, S, Larsimont, Denis, De Wind, Roland, Curigliano, G, André, F, Lacroix-Triki, M, Van de Vijver, Marc J, Rojo Fernandez, José Manuel, Floris, Giuseppe, Svatos, Bedrich, Sparano, Joseph, Rimm, David D.L., Nielsen, T, Kos, Z, Hewitt, Stephen M, Singh, Bal Ram, Farshid, G, Loibl, Sibylle, Allison, K H, Tung Ngu, Chan, Adams, S., Willard-Gallo, Karen, Horlings, HM, Gandhi, L, Moreira, A., Hirsch, F, Dieci, Maria V, Urbanowicz, M, Brcic, I, Korski, K, Gaire, F, Koeppen, A.H., Lo, A., Giltnane, Jennifer J.M., Rebelatto, MC, Steele, KE, Zha, J, Emancipator, K, Juco, JW, Denkert, Carsten, Reis-Filho, Jorge Sergio, Loi, Sherene, and Fox, Stephen B
- Abstract
info:eu-repo/semantics/published
- Published
- 2017
38. Bridge The Distance Between Breast Pathologists: When The Senopath Network Opens Up To The Telepathology : SY02.01 | Telepathology
- Author
-
Franchet, Camille, Quintyn-Ranty, M.-L., Caveriviere, P., Gordien, K., Frenois, F.-X., Maisongrosse, V., Mery, E., Wuithier, P., Reyre, J, Laborie, V., Rolland, V., Thibaut, I., Jamme-Lallemand, M., Palasse, J., Despax, B., Brousset, P., Lacroix-Triki, M., and Duprez-Paumier, R.
- Abstract
INTRODUCTION / BACKGROUND: In clinical practice, pathologists commonly face breast lesions, which are difficult to diagnose and which re- quire discussion. In Midi-Pyrénées, the largest region ofFrance, this problem has led us to develop in 2011 a peer group for breast diseases entitled SENOPATH. AIMS: In order to reduce second opinion delay, erase geographical barrier and provide continuing education, we aimed to introduce an effective online and outline telepathology system in the SENOPATH network. METHODS: A case review by SENOPATH can be requested by any pathologist in the Midi-Pyrénées region, by filling a form through the ONCOMIP network (organization dedicated to oncology in the Midi- Pyrénées region). The slides are sent for digitalization at The University Cancer Institute - Oncopole, using a Hamamatsu 2.0-RS scanner (until 2014) and a 3DHISTECH Pannoramic 250 scanner, then anonymized and transferred to a shared storage space at Toulouse Paul Sabatier University. Virtual slides can be seen before and/or after the meeting by members of the group by login in the online 3DHISTECHCaseCentervia the Imag’IN platform website. The group, who meets on a monthly basis, has recently developed a synchronized webinar (using 3DHISTECH Case Center and Pannoramic Viewer) coupled with a conference call in order to ease the attendance of pathologists from remote pathology laboratories. A consensual diagnosis and final pathology report are issued for each case and sent to the referent clinician via the patient medical file securely hosted by ONCOMIP. RESULTS: From January 2012 to December 2015, 211 cases (39 in 2012, 50 in 2013, 75 in 2014 and 47 in 2015) have been reviewed during 43 meetings. Ten out of 43 meetings (23%) used telepathology. Sixty-one cases out of 211 (29%) were actually digitalized, mainly using theHamamatsu2.0-RS scanner. In average, the number of attending pathologists was9 to 10from 2012 to 2015. The average number of cases reviewed per meeting was 3 in 2012 and 5 between 2013 and 2015. Two main motives for review were identified: diagnostic ‘routine difficulty’ (equivocal or discordant cases, invasive vs in situ lesion, atypical vs malignant lesions, immunohistochemistry scoring pitfalls) or rare tumours. The rare tumour category included among others syringomatous tumour of the nipple, low-grade adenosquamous, myoepithelial, mucoepidermoid or secretory carcinomas, adenomyoepithelioma, atypical microglandular adenosis, sclerosing papillary hyperplasia without myoepithelium and periductal stromal tumour. Molecular analyses requested by the group and implemented in the diagnosis process mainly included immunohistochemistry and fluorescence in situ hybridization (HER2, ETV6, MAML2, MYB). The SENOPATH network committee review for difficult or rare lesions of the breast has considerably improved the pathologist’s network in our region. This working group is regularly requested by oncologists to solve difficult cases. Our aims for the next few years are 1/ to digitalize all of the cases reviewed by the SENOPATH network, 2/ to use telepathology facilities provided by the Imag’IN platform in order to widen the group to a national level, and 3/ to construct a growing online library of virtual slides for breast challenging lesions.
- Published
- 2016
39. Does a very low dose of chronic I[superscript three]-irradiation induce a neuron loss in mice?
- Author
-
Collin, L., Lacroix-Triki, M., Caratero, C., Jozan, S., and Courtade, M.
- Subjects
Hippocampus (Brain) -- Research ,Rats -- Physiological aspects ,Rats -- Research ,Rattus -- Physiological aspects ,Rattus -- Research ,Neuroplasticity -- Research ,Irradiation -- Health aspects ,Petroleum, energy and mining industries - Abstract
Byline: L. Collin, M. Lacroix-Triki, C. Caratero, S. Jozan, M. Courtade Little is known about the effects of a very low dose of chronic irradiation on the brain. We have analysed brain sections from continuously irradiated (10 cGy/year - I[sup.3]-rays) and control C57Bl/6J mice at various times. We have established a neuron/astrocyte ratio in the CA1 of the hippocampus, measured the glutathione content of the hippocampus area and looked for the presence of PCNA-positive cells suggestive of immature stem cells. No difference was observed in the neurone/astrocyte ratio either with ageing or after irradiation. There was a significant increase in the glutathione content in the hippocampus area with ageing and after 24 months of irradiation. A slight increase of PCNA-positive cells was observed with ageing, especially after irradiation. These results suggest that a chronic very low dose of I[sup.3]-irradiation does not induce a neuron loss. Increased levels of glutathione and of PCNA-positive cells may suggest an adaptation of brain cells to the radiation factor.
- Published
- 2005
40. Abstract P6-09-05: Prognostic and predictive values of high endothelial venules (HEV) and tumor infiltrating CD8+ lymphocytes (CD8) in tumors of patients included in the adjuvant PACS04 trial: HEV is predictive of outcome for HER2+ tumors exposed to trastuzumab
- Author
-
Roché, HH, primary, Lafouresse, FF, additional, Filleron, T, additional, Laffont, R, additional, Maisongrosse, V, additional, Pichery, M, additional, Le Guellec, S, additional, Penault-Llorca, F, additional, Lemonnier, J, additional, Lacroix-Triki, M, additional, and Girard, J-P, additional
- Published
- 2017
- Full Text
- View/download PDF
41. Abstract P1-12-06: UCBG intergroup: 3-years efficacy results of the Unicancer-PACS08 trial including poor prognosis patients treated with docetaxel or ixabepilone in adjuvant setting
- Author
-
Campone, M, primary, Lacroix-Triki, M, additional, Roca, L, additional, Spielmann, M, additional, Wildiers, H, additional, Cottu, P, additional, Kerbrat, P, additional, Levy, C, additional, Mayer, F, additional, Bachelot, T, additional, Wiston, T, additional, Eymard, J-C, additional, Uwer, L, additional, Machiels, J-P, additional, Verhoeven, D, additional, Jaubert, D, additional, Facchini, T, additional, Orfeuvre, H, additional, Canon, J-L, additional, Asselain, B, additional, Lemonnier, J, additional, and Roché, H, additional
- Published
- 2016
- Full Text
- View/download PDF
42. Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma
- Author
-
Armand-Labit, V, primary, Meyer, N, additional, Casanova, A, additional, Bonnabau, H, additional, Platzer, V, additional, Tournier, E, additional, Sansas, B, additional, Verdun, S, additional, Thouvenot, B, additional, Hilselberger, B, additional, Doncescu, A, additional, Lamant, L, additional, Lacroix-Triki, M, additional, Favre, G, additional, and Pradines, A, additional
- Published
- 2016
- Full Text
- View/download PDF
43. Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification
- Author
-
Ng, CKY, Martelotto, LG, Gauthier, A, Wen, H-C, Piscuoglio, S, Lim, RS, Cowell, CF, Wilkerson, PM, Wai, P, Rodrigues, DN, Arnould, L, Geyer, FC, Bromberg, SE, Lacroix-Triki, M, Penault-Llorca, F, Giard, S, Sastre-Garau, X, Natrajan, R, Norton, L, Cottu, PH, Weigelt, B, Vincent-Salomon, A, Reis-Filho, JS, Ng, CKY, Martelotto, LG, Gauthier, A, Wen, H-C, Piscuoglio, S, Lim, RS, Cowell, CF, Wilkerson, PM, Wai, P, Rodrigues, DN, Arnould, L, Geyer, FC, Bromberg, SE, Lacroix-Triki, M, Penault-Llorca, F, Giard, S, Sastre-Garau, X, Natrajan, R, Norton, L, Cottu, PH, Weigelt, B, Vincent-Salomon, A, and Reis-Filho, JS
- Abstract
BACKGROUND: HER2 is overexpressed and amplified in approximately 15% of invasive breast cancers, and is the molecular target and predictive marker of response to anti-HER2 agents. In a subset of these cases, heterogeneous distribution of HER2 gene amplification can be found, which creates clinically challenging scenarios. Currently, breast cancers with HER2 amplification/overexpression in just over 10% of cancer cells are considered HER2-positive for clinical purposes; however, it is unclear as to whether the HER2-negative components of such tumors would be driven by distinct genetic alterations. Here we sought to characterize the pathologic and genetic features of the HER2-positive and HER2-negative components of breast cancers with heterogeneous HER2 gene amplification and to define the repertoire of potential driver genetic alterations in the HER2-negative components of these cases. RESULTS: We separately analyzed the HER2-negative and HER2-positive components of 12 HER2 heterogeneous breast cancers using gene copy number profiling and massively parallel sequencing, and identified potential driver genetic alterations restricted to the HER2-negative cells in each case. In vitro experiments provided functional evidence to suggest that BRF2 and DSN1 overexpression/amplification, and the HER2 I767M mutation may be alterations that compensate for the lack of HER2 amplification in the HER2-negative components of HER2 heterogeneous breast cancers. CONCLUSIONS: Our results indicate that even driver genetic alterations, such as HER2 gene amplification, can be heterogeneously distributed within a cancer, and that the HER2-negative components are likely driven by genetic alterations not present in the HER2-positive components, including BRF2 and DSN1 amplification and HER2 somatic mutations.
- Published
- 2015
44. 443TiP - First-in-human trial design for W0101: A first-in-class antibody-drug conjugate targeting IGF-1R and identification of the target patient population
- Author
-
Gomez-Roca, C.A., Garralda-Cabanas, E., Cruzalegui, F., Ausseil, F., Zorza, G., Delfour, O., Besse, J., Akla, B., Gautier, S., Adam, J., Lacroix-Triki, M., Passioukov, A., Roche, R., Pavlyuk, M., and Massard, C.
- Published
- 2018
- Full Text
- View/download PDF
45. Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis
- Author
-
Geyer, Fc, Lacroix Triki, M, Colombo, Pe, Patani, N, Gauthier, A, Natrajan, R, Lambros, Mb, Khalifeh, I, Albarracin, C, Orru, S, Marchio', Caterina, Sapino, Anna, Mackay, A, Weigelt, B, Schmitt, Fc, Wesseling, J, Sneige, N, and Reis Filho JS
- Subjects
microglandular adenosis ,Comparative Genomic Hybridization ,Breast Neoplasms ,basal-like ,Immunohistochemistry ,triple-negative tumors ,comparative genomic hybridization ,invasive ductal carcinoma ,Biomarkers, Tumor ,Cluster Analysis ,Humans ,Female ,Fibrocystic Breast Disease ,Precancerous Conditions - Abstract
Microglandular adenosis (MGA) is a proliferative breast lesion, which has been proposed to be a potential precursor of triple-negative breast cancers. The aims of this study were to determine whether MGAs harbour genetic alterations and if any such genetic aberrations found in MGAs are similar to those found in matched invasive carcinomas. Twelve cases of MGA and/or atypical MGA (AMGA), 10 of which were associated with invasive carcinoma, were evaluated. Immunohistochemical profiling revealed that all invasive carcinomas were of triple-negative phenotype and expressed S100, cytokeratins 8/18 and 'basal' markers. The morphologically distinct components of each case (MGA, AMGA and/or invasive carcinoma) were microdissected and subjected to microarray comparative genomic hybridization. Apart from three typical MGAs, all samples harboured genetic alterations. The percentage of the genome affected by copy number aberrations in MGA/AMGA ranged from 0.5 to 61.9%, indicating varying levels of genetic instability. In three cases, MGA/AMGA displayed copy number aberrations similar to those found in matched invasive components, providing strong circumstantial evidence that MGA may constitute the substrate for the invasive carcinoma development. Our results support the contention that MGA can be a clonal lesion and non-obligate precursor of triple-negative breast cancer.
- Published
- 2012
46. PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study
- Author
-
Lambros, M B, Natrajan, R, Geyer, F C, Lopez-Garcia, M A, Dedes, K J, Savage, K, Lacroix-Triki, M, Jones, R L, Lord, C J, Linardopoulos, S, Ashworth, A, Reis-Filho, J S, and University of Zurich
- Subjects
2734 Pathology and Forensic Medicine ,610 Medicine & health ,10174 Clinic for Gynecology - Published
- 2010
47. Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study
- Author
-
Dedes, K J, Lopez-Garcia, M A, Geyer, F C, Lambros, M B K, Savage, K, Vatcheva, R, Wilkerson, P, Wetterskog, D, Lacroix-Triki, M, Natrajan, R, Reis-Filho, J S, and University of Zurich
- Subjects
610 Medicine & health ,2730 Oncology ,1306 Cancer Research ,10174 Clinic for Gynecology - Published
- 2010
- Full Text
- View/download PDF
48. ASTER 70s UNICANCER phase III Trial: Can a genomic prognosticator help tailoring adjuvant systemic treatment for luminal breast carcinoma in elderly women?
- Author
-
Dubot, C., primary, Bourbouloux, E., additional, Mir, O., additional, Kirscher, S., additional, Rigal, O., additional, Ferrero, J.-M., additional, Curé, H., additional, Blot, E., additional, Allouache, D., additional, Cottu, P., additional, Romieu, G., additional, Lefeuvre, C., additional, Malaurie, E., additional, Tubiana-Mathieu, N., additional, Lacroix-Triki, M., additional, Rollot, F., additional, Peyro-Saint-Paul, H., additional, Orsini, C., additional, Bonnetain, F., additional, and Brain, E., additional
- Published
- 2014
- Full Text
- View/download PDF
49. Évaluation du BGJ398 dans le traitement des carcinomes épidermoïdes des voies aérodigestives supérieures : rôle de l’amplification de FGFR1 ?
- Author
-
Sadeler, A., primary, Thomas, F., additional, Hennebelle, I., additional, Lacroix-triki, M., additional, Thibault, B., additional, and Delord, J., additional
- Published
- 2014
- Full Text
- View/download PDF
50. Prediction of Recurrence with the Recurrence Score in Pre- and Post-Menopausal Patients from the Pacs01 Trial
- Author
-
Penault-Llorca, F., primary, Filleron, T., additional, Asselain, B., additional, Baehner, F., additional, Fumoleau, P., additional, Lacroix-Triki, M., additional, Butler, S., additional, Jamshidian, F., additional, Cherbavaz, D., additional, Roca, L., additional, Sagan, C., additional, Lemonnier, J., additional, Martin, A., additional, and Roche, H., additional
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.